2016
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP, Investigators C. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal Of The American College Of Cardiology 2016, 67: 1661-1671. PMID: 27012778, DOI: 10.1016/j.jacc.2015.12.068.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinClopidogrelDose-Response Relationship, DrugDrug Therapy, CombinationDyspepsiaFemaleGastrointestinal HemorrhageHumansIntestinal ObstructionIntestinal PerforationMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationOmeprazolePainPeptic UlcerPlatelet Aggregation InhibitorsProspective StudiesProton Pump InhibitorsStrokeTiclopidineConceptsDual antiplatelet therapyLow-dose aspirinProton pump inhibitorsMajor adverse cardiac eventsAdverse cardiac eventsPPI therapyAntiplatelet therapyAspirin usersGastrointestinal eventsCardiac eventsGI eventsMeier estimatesArtery diseaseCardiovascular endpointsLow-dose aspirin usersPrimary cardiovascular endpointUpper GI eventsHigh-dose aspirinPeripheral artery diseasePercutaneous coronary interventionCoronary artery diseaseHigh rateAspirin groupBlinded gastroenterologistsAspirin dose
2010
Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients. Alimentary Pharmacology & Therapeutics 2010, 32: 1240-1248. PMID: 20955443, DOI: 10.1111/j.1365-2036.2010.04465.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalArthritisCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesPyridinesRisk FactorsSulfonesTime FactorsUpper Gastrointestinal TractConceptsClinical eventsRisk factorsLow-dose aspirin useDouble-blind randomized trialsLong-term prospective studiesCox proportional hazards modelNonsteroidal anti-inflammatory drugsDiscontinuation of NSAIDsPredictors of discontinuationUpper GI eventsLow-dose aspirinPotential risk factorsProportional hazards modelAnti-inflammatory drugsAspirin useGI eventsPatient characteristicsArthritis patientsTreat analysisRandomized trialsRheumatoid arthritisProspective studyGI effectsDyspepsiaHazards model
2008
Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac
Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. Gastroenterology 2008, 135: 1517-1525. PMID: 18823986, DOI: 10.1053/j.gastro.2008.07.067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalConfidence IntervalsCyclooxygenase InhibitorsDiclofenacDose-Response Relationship, DrugEtoricoxibFemaleFollow-Up StudiesGastrointestinal HemorrhageHumansIncidenceMaleMiddle AgedOdds RatioOsteoarthritisProspective StudiesPyridinesRisk FactorsSulfonesTreatment OutcomeConceptsLower GI eventsClinical eventsGI eventsRisk factorsCOX-2 selective inhibitorsBlinded adjudication committeeLower Gastrointestinal EventsTraditional NSAID diclofenacUpper GI eventsDouble-blind trialSignificant risk factorsMajor risk factorAnti-inflammatory drugsSelective inhibitorNonsteroidal anti-inflammatory drug diclofenacGastrointestinal eventsNSAID useProspective trialMultivariable analysisRheumatoid arthritisAdjudication committeeMean durationCyclo-oxygenaseNSAID diclofenacAbstractText
2006
GI Risk and Risk Factors of NSAIDs
Laine L. GI Risk and Risk Factors of NSAIDs. Journal Of Cardiovascular Pharmacology 2006, 47: s60-s66. PMID: 16785831, DOI: 10.1097/00005344-200605001-00011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI eventsClinical eventsNSAID useGI eventsRisk factorsMultiple nonsteroidal anti-inflammatory drugsNon-NSAID analgesicsUpper GI symptomsUse of coxibsUpper gastrointestinal complicationsUse of corticosteroidsRegular NSAID useImportant risk factorLowest effective doseAnti-inflammatory drugsGastrointestinal complicationsGI symptomsAnnual incidenceRisk stratificationGI riskRelative riskPrior historyEffective doseOlder age
2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 1006-1012. PMID: 12360461, DOI: 10.1053/gast.2002.36013.Peer-Reviewed Original ResearchConceptsUpper GI eventsClinical upper GI eventsSelective cyclooxygenase-2 inhibitorHigh-risk patientsGI eventsRisk factorsCyclooxygenase-2 inhibitorClinical characteristicsRheumatoid arthritisClinical eventsNonsteroidal anti-inflammatory drugsClinical GI eventsRisk of NSAIDUpper GI complicationsLow-risk patientsSevere rheumatoid arthritisPatients' clinical characteristicsRheumatoid arthritis patientsAbsolute risk reductionLow-risk subgroupsAnti-inflammatory drugsIndividual risk factorsRisk of eventsGI complicationsNonselective NSAIDs
2001
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120: 594-606. PMID: 11179238, DOI: 10.1053/gast.2001.21907.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsGI eventsGI diseasePrevention of NSAIDAnti-inflammatory drug useClinical upper GI eventsHistory of ulcerUpper GI eventsHalf of patientsHigh-risk patientsAnti-inflammatory drugsGastrointestinal eventsNSAID doseGastroduodenal injuryNSAID usersClinical featuresGastric erosionsSteroid useCommon causeDrug usePatientsUlcersDiseaseRiskUnited States today